Ovarian Cancer

A modified intraperitoneal (IP) regimen for advanced ovarian cancer demonstrated feasibility, tolerability, and evidence of effectiveness, results of a small pilot study suggest.

Recent clinical and economic studies have suggested that ovarian cancer regimens containing bevacizumab could fall within the boundaries of cost-effectiveness, at least for some patients.

A chronic shortage of the most commonly used taxane for ovarian cancer would add almost $9 million a month to the cost of care if half of newly diagnosed cases were affected.

Dr. Eric Pujade-Lauraine, from Université de Paris Descartes, France, on the AURELIA Bevacizumab Trial for Platinum-Resistant Ovarian Cancer.

Combining bevacizumab with standard chemotherapy reduced the risk of disease progression by 52% in patients with platinum-resistant ovarian cancer.

Dr. Nancy Davidson, from the University of Pittsburgh Cancer Institute, on Screening for Ovarian Cancer

Detecting hereditary cancer and providing genetic counseling can help prevent a new primary cancer and may also help to protect family members from developing cancer.

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.

Understanding the genetic basis of breast and ovarian cancers is essential to providing patients with effective preventive and/or management strategies that can improve outcomes.

Despite initial disappointing findings on overall survival, PARP inhibitors remains under active investigation for patients with ovarian cancer.

The US Supreme Court has asked an appellate court to reconsider its decision regarding patents held on two genes.

Researchers are reporting better survival rates in women with invasive EOC and germline mutations in the tumor suppressor genes BRCA1 and BRCA2 than in patients who are noncarriers.

Dr. Michael Birrer from Massachusetts General Hospital Cancer Center on the Ovarian Cancer Avastin OS Benefit

Bevacizumab has failed to demonstrate statistically significant improvements in OS for women with recurrent ovarian cancer in 2 recent clinical trials.

Bevacizumab improved progression-free survival in patients with ovarian cancer but was not shown to affect overall survival.

Dr. Michael Birrer, from Massachusetts General Hospital Cancer Center, Discusses the GOG0218 and ICON7 Trials

Patients with ovarian cancer who express BRCA1/2 mutations demonstrated a better overall survival after 5 years.

Dr. Michael Birrer, from Massaschusetts General Hospital Cancer Center, Discusses Recurrent Ovarian Cancer Treatment

Half of all women with advanced ovarian cancer who develop brain cancer have a single metastasis to the brain.

Subfertile women who undergo ovarian stimulation for in vitro fertilization have an increased risk of ovarian malignancies.

Bevacizumab (Avastin) improved progression-free survival (PFS) in patients with ovarian cancer but was not shown to affect overall survival (OS), according to a new study...

Primary care physicians in the US adhere poorly to established guidelines for genetic counseling and testing for women who are at high risk of breast and ovarian cancer.

This report highlights 5 abstracts relevant to the current and future management of patients with female pelvic malignancies.

Personal perspectives from oncology nurses of abstracts presented at ASCO on research with the potential to change practice, important studies that failed to meet expectations, and topics particularly relevant to oncology nurses.

Concurrent and continued bevacizumab added to standard chemotherapy with carboplatin/ paclitaxel improved OS in women with high-risk ovarian cancer, according to an interim survival analysis of the ICON7 trial.